Johnson & Johnson (JNJ) and Protagonist Therapeutics (PTGX) said Friday their jointly developed drug icotrokinra largely met its primary endpoint of significant skin clearance in a phase 3 study of adults and adolescents with moderate or greater plaque psoriasis on high-impact skin areas.
The 16-week study showed 57% of patients treated with icotrokinra showed clear or almost clear skin compared with 6% for those receiving a placebo, the companies said.
The drug also showed a "favorable" safety profile comparable to the placebo, the companies said.
Protagonist said it expects to submit a new drug application for icotrokinra with the US Food and Drug Administration this year.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。